Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.
about
No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapyProspective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer.Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy.Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre.Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy.Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity.Reducing rectal injury during external beam radiotherapy for prostate cancer.Hypofractionated radiotherapy for prostate cancer.Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients.Current role of spacers for prostate cancer radiotherapy.Spacer application for prostate cancer radiation therapy.Current standards and future directions for prostate cancer radiation therapy.Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients.Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.Treatment planning after hydrogel injection during radiotherapy of prostate cancer.Erectile dysfunction after prostate three-dimensional conformal radiation therapy. Correlation with the dose to the penile bulb.[Use of hydrogel as spacer in Denovier's space: optimization of IMRT radiotherapy of localized prostate cancer].Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.Transurethral resection of the prostate after radiotherapy for prostate cancer: impact on quality of life.Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer.Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis.Assessment of accuracy and efficiency of atlas-based autosegmentation for prostate radiotherapy in a variety of clinical conditions.Impact of inter- and intrafraction deviations and residual set-up errors on PTV margins. Different alignment techniques in 3D conformal prostate cancer radiotherapy.Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.[Current requirements for image management in radiotherapy].Risk factors related to interfractional variation in whole pelvic irradiation for locally advanced pelvic malignancies.Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer.11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients
P2860
Q31083823-5FBBE77D-FA1F-4453-A480-2385D649ABF4Q34556112-362EA3A4-010D-4FFE-BF2F-D598BF7A2928Q34793072-10AD107A-A319-4426-BA22-6AB43805FCB5Q35812261-C914D1B7-759C-4DE8-BB35-2F82DDAFDE9FQ37137423-E5E31CC2-849A-4795-8F1A-F9B446303119Q37979128-B2C3A1C5-FD48-42F1-A167-CA86BFE15563Q38036587-43CBB9E1-A7CB-48B9-84D5-3D33B6ED19B2Q38106626-A052A349-18CA-438F-8201-26A8361E5102Q38283897-818A4B09-AAEF-4A31-AFE2-F4D3F19DEE8EQ38788456-EA056288-A009-4763-B70B-BF684CF1E8B7Q38931064-8D2C47A0-D990-4401-A24A-E600CC0007A0Q39198013-062A1AF7-C827-471D-AB84-EDA5B1B9550CQ39499604-75D0C7C3-4892-45A5-B1BF-AC55E8953D94Q40162552-AA1AB189-5064-404E-BBD5-57B6A66F70CBQ40374061-3F34AA64-415C-4F60-9A45-042DB51EFC01Q43410693-07F83CC6-2335-4F49-93FA-9BABB6190717Q43428276-A8B60B21-9C01-43FE-9A81-3381296E1085Q46149480-D882E146-D3FF-42BC-B0A9-ABA5769546FFQ47327130-EA4B0FE3-840A-4494-97BB-450A29D21375Q47802807-5CA45B39-EE9C-43DB-B50F-12661F49F3F1Q48075929-2F4CBB88-C518-43EC-9B77-4AB2501F98E6Q48080139-2157DF2B-7DF7-423C-A436-C570A6ED29EAQ48271324-95579D8F-8B8F-49B6-B2E2-394F1D6D04B4Q48352941-CAB7FF2A-ADE8-4F6C-8D7B-1D43C6B64B71Q48394956-041963EF-0795-4D3D-8D62-48A0DAF51505Q51358540-09097481-4F2F-49D0-9FE5-583FF934CE36Q53119315-439DA081-6E4F-4C60-AE3F-FF58038FE870Q53137626-7C840D0A-9BD8-44F2-AA6B-D90C6970F41EQ53168760-316778B5-326A-4E2F-87B5-F8E524299850Q53176035-5D8F1148-EF00-4831-B8DE-68640534952CQ53406446-2A02414F-53EC-45FF-A2A1-0411904AC8B7Q57780536-4332342C-7714-4F5E-A729-20412721D310
P2860
Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Combination of dose escalation ...... patients with prostate cancer.
@en
Combination of dose escalation with technological advances
@nl
type
label
Combination of dose escalation ...... patients with prostate cancer.
@en
Combination of dose escalation with technological advances
@nl
prefLabel
Combination of dose escalation ...... patients with prostate cancer.
@en
Combination of dose escalation with technological advances
@nl
P2093
P2860
P1476
Combination of dose escalation ...... patients with prostate cancer.
@en
P2093
Barbara Krenkel
Jens Klotz
Marc D Piroth
Michael J Eble
Michael Pinkawa
Richard Holy
Victoria Djukic
P2860
P2888
P304
P356
10.1007/S00066-011-2249-Z
P577
2011-07-25T00:00:00Z